Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
SUPN > SEC Filings for SUPN > Form 8-K on 27-Jan-2014All Recent SEC Filings

Show all filings for SUPERNUS PHARMACEUTICALS INC

Form 8-K for SUPERNUS PHARMACEUTICALS INC


27-Jan-2014

Change in Directors or Principal Officers, Other Events, Financial S


Item 5.02 Departure of Directors and Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(e) Modification of Compensatory Arrangements with Executive Officers

On January 21 and 23, 2014 the Compensation Committee of Supernus Pharmaceuticals, Inc. (the "Company") approved modifications of the compensation of its executive officers, as follows:

The annual base salary of Jack A. Khattar, the Company's President and Chief Executive Officer, was increased from $463,500 to $486,675. Mr. Khattar was awarded a 2013 bonus of $231,750 and was granted options to purchase 150,000 shares of common stock.

The annual base salary of Gregory S. Patrick, the Company's Vice President and Chief Financial Officer, was increased from $309,000 to $318,270. Mr. Patrick was awarded a 2013 bonus of $109,020 and was granted options to purchase 50,000 shares of common stock.

The annual base salary of Stefan K.F. Schwabe, MD, Ph.D., the Company's Executive Vice President and Chief Medical Officer, was increased from $332,875 to $342,860. Dr. Schwabe was awarded a 2013 bonus of $111,850 and was granted options to purchase 40,000 shares of common stock. In addition, Dr. Schwabe's bonus target for 2014 was increased to 40% of his base salary compared with 35% in 2013.

The annual base salary of Padmanabh P. Bhatt, Ph.D., the Company's Senior Vice President, Intellectual Property and Chief Scientific Officer, was increased from $315,180 to $324,635. Dr. Bhatt was awarded a 2013 bonus of $90,770 and was granted options to purchase 30,000 shares of common stock.

The annual base salary of Jones W. Bryan, Ph.D., the Company's Vice President of Business Development, was increased from $257,500 to $265,225. Dr. Bryan was awarded a 2013 bonus of $72,620 and was granted options to purchase 30,000 shares of common stock.

The annual base salary of Victor L. Vaughn, the Company's Senior Vice President of Sales, was increased from $275,000 to $283,250. Dr. Bryan was awarded a 2013 bonus of $74,250 and was granted options to purchase 30,000 shares of common stock.

These increases were the result of the Compensation Committee's annual compensation review for executive officers. These increases in annual base salary became effective on January 1, 2014. Vesting for all stock option grants will occur annually in equal increments over a four year period. The exercise price for Mr. Khattar's grant is $9.56 per share, based on the closing price of January 23, 2014, the date of approval of the grants by the full board of directors. All other executive officers grants are $9.24 per share, based on the closing price of January 21, 2014, the date of approval of the grants by the full board of directors. All other terms and conditions of the Company's compensatory arrangements with these executive officers remain unchanged.




Item 8.01 Other Events.

On January 27, 2014, Supernus issued a press release announcing the issuance of a European patent and Canadian patent for SPN-812, its novel non-stimulant product candidate for the treatment of ADHD. These patents will provide protection for the product with expiration that is no earlier than 2029. Supernus has several additional patent applications for SPN-812 pending in other geographic regions, including the United States. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following document is furnished as an Exhibit pursuant to Item 8.01 hereof:

Exhibit 99.1 - Press Release Dated January 27, 2014 of the Company.


  Add SUPN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for SUPN - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.